ARCALYST Performance and Market - ARCALYST has achieved approximately $1.5 billion in net revenue since its launch and is on track to become a blockbuster[7] - ARCALYST has only about 18% penetration into the multiple recurrence population, indicating continued growth potential[7] - The company anticipates ARCALYST revenue between $900 million and $920 million in 2026[7] - Approximately 80% of patients on ARCALYST were prescribed the drug when they had 2 or more recurrences, while about 20% were prescribed on their 1st recurrence[27] - In Q4 2025, ARCALYST net revenue reached $202.1 million, representing approximately 65% year-over-year growth[32] Financial Position and Pipeline - The company reported approximately $414 million in cash reserves at the end of 2025[8] - KPL-387, is currently in a Phase 2/3 trial, with Phase 2 data expected in the second half of 2026[7] - KPL-1161 Phase 1 first-in-human trial is expected to initiate by the end of 2026[7] KPL-387 Development - Approximately 75% of recurrent pericarditis patients prefer the KPL-387 target profile over available commercial and investigational therapies[58] - Approximately 75% of ARCALYST-naïve patients would be more willing to take an injectable therapy if presented in an autoinjector[59] - Approximately 70% of healthcare providers report a high likelihood of prescribing KPL-387 for new patients[60]

Corporate Presentation for JPM January 2026 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended (the "Act"). Forward-looking statements are statements that are not of historical fact and include, without limitation, statements regarding future events, our future financial condition, results of operations, business strategy and plans, prospective products (as well as their potential to achiev ...

NASDAQ: CPRX January 2026 Improving the Lives of Patients Living with Rare Diseases Safe Harbor This presentation contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are outside our control. All statements regarding our strategy, future operations, financial position, estimated revenues or losses, projected costs, prospects, plans, and objectives, other than statements of historical fact included in our filings with the U.S. Securities and Exchange Comm ...

EVERY BREAKTHROUGH BEGINS WITH BELIEF January 2026 Corporate Presentation Disclaimer Forward Looking Statements This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current expectations and beliefs of the management of Neurogene, as well as assumptions made by, and ...

© 2 0 2 6 O R U K A T H E R A P E U T I C S Disclaimers The information contained in this presentation has been prepared by Oruka Therapeutics, Inc. (the "Company") and contains information pertaining to the business and operations of the Company. The information contained in this presentation: (a) is provided as at the date hereof, is subject to change without notice, and is based on publicly available information, internally developed data as well as third party information from other sources; (b) does no ...

Bicycle Therapeutics Investor Presentation • January 2026 Forward-looking statements This presentation may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts", "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that a ...

Corporate Presentation Financial Discipline and Opportunistic Innovation * RYTELO® (imetelstat) is approved in the U.S. and the EU for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. See U.S. Prescribing Information and Medication Guide: https://pi.geron.com/products/US/pi/rytelo_pi.pdf; see Summary of Product Characteristics for RYTELO in the EU: https://pi.geron.com/products/rytelo/eu/rytelo_smpc_eu.pdf o $220M-$240M in expected ...

ADMA Biologics Realizing the Potential of Specialty Biologics with Groundbreaking Immunotechnology January 2026 NASDAQ: ADMA Forward-Looking Statements This presentation contains "forward-looking statements" pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. and its subsidiaries (collectively, "we," "our" or the "Company"), including, without limitation, statements that may predict, forecast, indicate, or imply future results, performan ...

January 9, 2026 Zanidatamab: Pivotal Phase 3 HERIZON-GEA-01 Trial Results in Gastroesophageal Adenocarcinoma (GEA) Innovating to Transform the Lives of Patients and Their Families Intended for U.S. investor audiences only. Intended for U.S. investor audiences only. 2 January 9, 2026 Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the C ...

KalVista Pharmaceuticals Corporate Overview January 2026 1 Forward-looking statements This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to our management. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be ...